Bone Biologics Corporation (BBLG)
NASDAQ: BBLG · IEX Real-Time Price · USD
2.130
+0.060 (2.90%)
At close: Mar 28, 2024, 3:49 PM
2.250
+0.120 (5.63%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Bone Biologics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014 2013 - 2007
Cash & Equivalents
3.037.546.6800.020.960.690.621.122.66
Upgrade
Cash & Cash Equivalents
3.037.546.6800.020.960.690.621.122.66
Upgrade
Cash Growth
-59.85%12.93%---97.47%38.40%11.27%-44.37%-58.10%172942.65%
Upgrade
Receivables
0000000000.08
Upgrade
Other Current Assets
0.710.96000.010.090.110.080.431.07
Upgrade
Total Current Assets
3.748.56.6800.031.040.80.71.543.81
Upgrade
Property, Plant & Equipment
000000000.010.01
Upgrade
Total Long-Term Assets
000000000.010.01
Upgrade
Total Assets
3.748.56.6800.031.040.80.71.553.82
Upgrade
Accounts Payable
0.360.10.11.720.390.20.720.260.320.22
Upgrade
Current Debt
00011.720901.203.66
Upgrade
Other Current Liabilities
0.472.4400.250.190.440.240.041.820
Upgrade
Total Current Liabilities
0.832.550.113.690.589.640.961.52.153.87
Upgrade
Long-Term Debt
000011.3208.237.565.083.65
Upgrade
Total Long-Term Liabilities
000011.3208.237.565.083.65
Upgrade
Total Liabilities
0.832.550.113.6911.99.649.199.067.237.52
Upgrade
Total Debt
00011.7211.3298.238.765.087.3
Upgrade
Debt Growth
---3.56%25.78%9.36%-6.09%72.41%-30.42%75.18%
Upgrade
Retained Earnings
-80.91-71.96-70.48-68.86-67.04-63.62-59.19-52.13-25.91-12.04
Upgrade
Shareholders' Equity
2.915.956.58-13.69-11.87-8.6-8.4-8.36-5.68-3.7
Upgrade
Net Cash / Debt
3.037.546.68-11.72-11.3-8.04-7.54-8.14-3.97-4.64
Upgrade
Net Cash / Debt Growth
-59.85%12.93%--------
Upgrade
Net Cash Per Share
11.50158.18352.75-966.43-929.62-960.44-1161.88-1298.25-836.35-1863.21
Upgrade
Working Capital
2.915.956.58-13.69-0.55-8.6-0.17-0.8-0.6-0.06
Upgrade
Book Value Per Share
11.04124.79347.46-1128.76-976.68-1026.52-1293.91-1333.56-1197.61-1484.15
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).